OncoMatch/Clinical Trials/NCT06375044
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT06375044 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SIM0500 for relapsed or refractory multiple myeloma.
Treatment: SIM0500 — This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Florida · Jacksonville, Florida
- Dana Farber Cancer institution · Boston, Massachusetts
- Mayo Clinic Rochester · Rochester, Minnesota
- Mayo Clinic Arizona · Phoenix, Arizona
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify